nach oben

Medical Oncology

Erschienen in:

01.09.2008 | Review

Bisphosphonate treatment and radiotherapy in metastatic breast cancer

verfasst von: A. Ugur Ural, Ferit Avcu, Yusuf Baran

Erschienen in: Medical Oncology | Ausgabe 3/2008

Einloggen, um Zugang zu erhalten

Abstract

Patients with advanced breast cancer frequently develop metastasis to bone. Bone metastasis results in intractable pain and high risk of pathologic fractures due to osteolysis. The treatment of breast cancer patients with bone metastases requires a multidisciplinary approach. Radiotherapy is an established treatment for metastatic bone pain. It may be delivered either as a localized low dose treatment for localized bone pain or systemically for more widespread symptoms. Bisphosphonates have been shown to reduce morbidity and bone pain from bone metastases when given to patients with metastatic bone disease. In vivo studies indicate that early bisphosphonates administration in combination with radiotherapy improves remineralization and restabilization of osteolytic bone metastases in animal tumor models. This review focused on a brief discussion about biology of bone metastases, the effects of radiotherapy and bisphosphonate therapy, and possible mechanisms of combination therapy in metastatic breast cancer patients.

Jemal A, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005;55(1):10–30.PubMed

Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev. 2001;27(3):165–76.PubMedCrossRef

Cicek M, Oursler MJ. Breast cancer bone metastasis and current small therapeutics. Cancer Metastasis Rev. 2006;25(4):635–44.PubMedCrossRef

Hsu H, et al. Tumour necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA. 1999;96(7):3540–45.PubMedCrossRef

Lacey DL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998;93(2):165–76.PubMedCrossRef

Simonet WS, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997;89(2):309–19.PubMedCrossRef

Guise TA, et al. Parathyroid hormone-related protein (PTHrP)(1–139) isoform is efficiently secreted in vitro and enhances breast cancer metastasis to bone in vivo. Bone. 2002;30(5):670–6.PubMedCrossRef

Pederson L, et al. Identification of breast cancer cell line-derived paracrine factors that stimulate osteoclast activity. Cancer Res. 1999;59(22):5849–55.PubMed

Mercer RR, Miyasaka C, Mastro AM. Metastatic breast cancer cells suppress osteoblast adhesion and differentiation. Clin Exp Metastasis. 2004;21(5):427–35.PubMedCrossRef

10.

Mastro AM, et al. Breast cancer cells induce osteoblast apoptosis: a possible contributor to bone degradation. J Cell Biochem. 2004;91(2):265–76.PubMedCrossRef

11.

Hoskin PJ. Bisphosphonates and radiation therapy for palliation of metastatic bone disease. Cancer Treat Rev. 2003;29(4):321–7.PubMedCrossRef

12.

Luini A, et al. The evolution of the conservative approach to breast cancer. Breast. 2007;16(2):120–9.PubMedCrossRef

13.

Vukmirovic-Popovic S, et al. Morphological, histomorphometric, and microstructural alterations in human bone metastasis from breast carcinoma. Bone. 2002;31(4):529–35.PubMedCrossRef

14.

Krempien R, et al. Combination of early bisphosphonate administration and irradiation leads to improved remineralization and restabilization of osteolytic bone metastases in an animal tumor model. Cancer. 2003;98(6):1318–24.PubMedCrossRef

15.

Pandit-Taskar N, Batraki M, Divgi CR. Radiopharmaceutical therapy for palliation of bone pain from osseous metastases. J Nucl Med. 2004;45(8):1358–65.PubMed

16.

Li L, Story M, Legerski RJ. Cellular responses to ionizing radiation damage. Int J Radiat Oncol Biol Phys. 2001;49(4):1157–62.PubMedCrossRef

17.

Hoskin PJ, Ford HT, Harmer CL. Hemibody irradiation (HBI) for metastatic bone pain in two histologically distinct groups of patients. Clin Oncol (R Coll Radiol). 1989;1(2):67–9.

18.

Hoskin PJ, et al. A prospective randomised trial of 4 Gy or 8 Gy single doses in the treatment of metastatic bone pain. Radiother Oncol. 1992;23(2):74–8.PubMedCrossRef

19.

Arcangeli G, et al. The responsiveness of bone metastases to radiotherapy: the effect of site, histology and radiation dose on pain relief. Radiother Oncol. 1989;14(2):95–101.PubMedCrossRef

20.

Hoskin PJ, et al. Effect of local radiotherapy for bone pain on urinary markers of osteoclast activity. Lancet. 2000;355(9213):1428–9.PubMedCrossRef

21.

Ural AU, Avcu F. Evolving therapeutic role of bisphosphonates in multiple myeloma. Br J Cancer. 2005;93(2):267–8.PubMedCrossRef

22.

Sato M, et al. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest. 1991;88(6):2095–105.PubMedCrossRef

23.

Bukowski JF, Dascher CC, Das H. Alternative bisphosphonate targets and mechanisms of action. Biochem Biophys Res Commun. 2005;328(3):746–50.PubMedCrossRef

24.

Green JR. Preclinical pharmacology of zoledronic acid. Semin Oncol. 2002;29(6 Suppl 21):3–11.PubMedCrossRef

25.

Ural AU, Avcu F. Bisphosphonates may potentiate radiation effects: a new approach in cancer treatment? Biochem Biophys Res Commun. 2005;336(2):373–4.PubMedCrossRef

26.

Li X, et al. Inhibition of protein geranylgeranylation and RhoA/RhoA kinase pathway induces apoptosis in human endothelial cells. J Biol Chem. 2002;277(18):15309–16.PubMedCrossRef

27.

Carteni G, et al. Efficacy and safety of zoledronic acid in patients with breast cancer metastatic to bone: a multicenter clinical trial. Oncologist. 2006;11(7):841–8.PubMedCrossRef

28.

Vinholes JJ, et al. Relationships between biochemical and symptomatic response in a double-blind randomised trial of pamidronate for metastatic bone disease. Ann Oncol. 1997;8(12):1243–50.PubMedCrossRef

29.

Ural AU, et al. The bisphosphonate zoledronic acid induces cytotoxicity in human myeloma cell lines with enhancing effects of dexamethasone and thalidomide. Int J Hematol. 2003;78(5):443–9.PubMed

30.

Dhodapkar MV, et al. Anti-myeloma activity of pamidronate in vivo. Br J Haematol. 1998;103(2):530–2.PubMedCrossRef

31.

Kunzmann V, et al. Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood. 2000;96(2):384–92.PubMed

32.

Mundy GR, Yoneda T. Bisphosphonates as anticancer drugs. N Engl J Med. 1998;339(6):398–400.PubMedCrossRef

33.

Avcu F, et al. The bisphosphonate zoledronic acid inhibits the development of plasmacytoma induced in BALB/c mice by intraperitoneal injection of pristane. Eur J Haematol. 2005;74(6):496–500.PubMedCrossRef

34.

Magnetto S, et al. Additive antitumor activities of taxoids in combination with the bisphosphonate ibandronate against invasion and adhesion of human breast carcinoma cells to bone. Int J Cancer. 1999;83(2):263–9.PubMedCrossRef

35.

van der Pluijm G, et al. Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest. 1996;98(3):698–705.PubMedCrossRef

36.

Ural AU, et al. In vitro synergistic cytoreductive effects of zoledronic acid and radiation on breast cancer cells. Breast Cancer Res. 2006;8(4):R52.PubMedCrossRef

37.

Woodward JK, et al. Combined effects of zoledronic acid and doxorubicin on breast cancer cell invasion in vitro. Anticancer Drugs. 2005;16(8):845–54.PubMedCrossRef

38.

Jagdev SP, et al. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer. 2001;84(8):1126–34.PubMedCrossRef

39.

Ural AU, Avcu F. Additive/synergistic anti-tumoral effects of the combination of docetaxel and zoledronic acid on prostate cancer cells: possible mechanisms? Acta Oncol. 2006;45(4):491–2.PubMedCrossRef

40.

Algur E, Macklis RM, Hafeli UO. Synergistic cytotoxic effects of zoledronic acid and radiation in human prostate cancer and myeloma cell lines. Int J Radiat Oncol Biol Phys. 2005;61(2):535–42.PubMed

41.

Ural AU, Avcu F. Radiosensitizing effect of zoledronic acid in small cell lung cancer. Lung Cancer 2005;50(2):271–2.PubMedCrossRef

42.

Kurdoglu B, et al. Apoptosis as a predictor of paclitaxel-induced radiosensitization in human tumor cell lines. Clin Cancer Res. 1999;5(9):2580–7.PubMed

43.

McKenna WG, Muschel RJ. Targeting tumor cells by enhancing radiation sensitivity. Genes Chromosomes Cancer. 2003;38(4):330–8.PubMedCrossRef

44.

Bernhard EJ, et al. The farnesyltransferase inhibitor FTI-277 radiosensitizes H-ras-transformed rat embryo fibroblasts. Cancer Res. 1996;56(8):1727–30.PubMed

45.

Journe F, et al. Sequence- and concentration-dependent effects of acute and long-term exposure to the bisphosphonate ibandronate in combination with single and multiple fractions of ionising radiation doses in human breast cancer cell lines. Clin Exp Metastasis. 2006;23(2):135–47.PubMedCrossRef

46.

Hillner BE, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003.;21(21):4042–57.PubMedCrossRef

47.

Kouloulias V, et al. Radiotherapy in conjunction with intravenous infusion of 180 mg of disodium pamidronate in management of osteolytic metastases from breast cancer: clinical evaluation, biochemical markers, quality of life, and monitoring of recalcification using assessments of gray-level histogram in plain radiographs. Int J Radiat Oncol Biol Phys. 2003;57(1):143–57.PubMed

Titel: Bisphosphonate treatment and radiotherapy in metastatic breast cancer
verfasst von: A. Ugur Ural
Ferit Avcu
Yusuf Baran
Publikationsdatum: 01.09.2008
Verlag: Humana Press Inc
Erschienen in: Medical Oncology / Ausgabe 3/2008
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-008-9044-4

Springer Medizin

Bisphosphonate treatment and radiotherapy in metastatic breast cancer

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2008

Clinical significance of serum MMP-2 and MMP-7 in patients with ovarian cancer

A phase II study of sequential docetaxel and gemcitabine followed by docetaxel and carboplatin as first-line therapy for non-small cell lung cancer

Systematic review to establish the safety profiles for direct and indirect inhibitors of p38 Mitogen-activated protein kinases for treatment of cancer

The results of three different treatment modalities in patients with locally advanced nasopharyngeal carcinoma

Prostate cancer

Primary mediastinal large B-cell lymphoma mimicking liposarcoma

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie